PAM
SRPT icon

Paradigm Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Paradigm Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,000
Closed -$183K – 870
2015
Q2 		$183K Hold
6,000
– – 0.02% 468
2015
Q1 		$79.7K Buy
+6,000
New +$80K 0.01% 586

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Paradigm Asset Management's SRPT Position: Q3 2015 in Review

Paradigm Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2015, closing a stake of 6,000 shares — an estimated $183K sold.

Paradigm Asset Management first reported a position in SRPT in Q1 2015 and held it in 2 quarters. The position peaked at $183K in Q2 2015. 149 funds tracked by Wall St. Rank hold SRPT as of Q3 2015.

  • Paradigm Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 6,000 Sarepta Therapeutics shares in Q3 2015, an estimated $183K.
  • Paradigm Asset Management first reported a position in Sarepta Therapeutics in Q1 2015 and held it in 2 quarters.
  • Paradigm Asset Management's Sarepta Therapeutics position peaked at $183K in Q2 2015.
  • 149 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2015.

Based on Paradigm Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.